Botanix Investor Centre

Botanix Pharmaceuticals is a clinical stage dermatology company developing novel treatments for common skin diseases and infection leveraging its novel delivery technology, Permetrex™.

Our goal is to unlock the true potential of synthetic cannabinoids for people around the world, with an evidence-first approach. Our shareholders are valued partners in our Company, so we invite you to explore our Investor Centre, subscribe to our email updates and we will keep you updated with our progress.

ASX: BOT | Share price


Feb 4, 2021
April 6, 2017
December 9, 2019
September 17, 2019
January 31, 2019
November 15, 2018
August 13, 2018
April 9, 2018
November 13, 2017

Latest video

DEAL NEWS | Pfizer enters CBD market

At Botanix, we genuinely believe in the therapeutic potential…

AMR: the next global pandemic?

While the world continues to battle COVID-19, experts are concerned…

Investor Roadshow Presentation

Botanix has today released an updated corporate presentation…


According to WHO Director-General Tedros Adhanom Ghebreyesus,…

MEET THE TEAM | Lynda Berne, Head of Commercial

With a successful track record of commercialising therapies…

AGM Presentation

Botanix Pharmaceuticals (ASX:BOT) is today hosting its Annual…

Vince Ippolito speaks with Proactive

Botanix President and Executive Chairman, Vince Ippolito, was…

Dermatology Update

Botanix Pharmaceuticals (ASX:BOT) has today provided an update…

Interested in investing? Check out our latest investor presentation

Sign up to receive our latest news

Thank you! Your subscription has been confirmed. You'll hear from us soon.